J Alzheimers Dis:艾司西酞普兰不能改善抑郁性AD的情绪和认知

2016-10-28 MedSci MedSci原创

背景:有效治疗抑郁性阿尔茨海默氏病(AD)患者的方法较少。目的:调查艾司西酞普兰治疗抑郁性AD患者的疗效和耐受性。方法:在这为期12周的随机、双盲、安慰剂对照试验及开放的,超过12周的探索性试验,纳入年龄超过50岁的AD患者,按照奥林的诊断标准定义抑郁症的患者。应用评估痴呆患者抑郁的康奈尔量表(CSDD),及其他的抑郁和认知量表进行重复。结果:对91名受试者进行了筛选,84例受试者随机分为研究组或

背景:有效治疗抑郁性阿尔茨海默氏病(AD)患者的方法较少。

目的:调查艾司西酞普兰治疗抑郁性AD患者的疗效和耐受性。

方法:在这为期12周的随机、双盲、安慰剂对照试验及开放的,超过12周的探索性试验,纳入年龄超过50岁的AD患者,按照奥林的诊断标准定义抑郁症的患者。应用评估痴呆患者抑郁的康奈尔量表(CSDD),及其他的抑郁和认知量表进行重复。

结果:对91名受试者进行了筛选,84例受试者随机分为研究组或安慰剂组(每组n = 42  )。24例(29%)受试者未完成研究, 60例受试者完成了研究(研究组:N = 27;安慰剂组:N  = 33)。在12周时,两组患者抑郁和认知的差异无统计学意义。然而,探索性分析表明,进一步研究子课题“明确抑郁症”(基线CSDD评分≥18)是必要的。两组间与治疗相关的不良事件(AE)无显著性差异(P = 0.83  ),并且没有观察到严重的治疗相关AE。

结论:抑郁性的痴呆患者应用艾司西酞普兰改善抑郁的效果并不明显。未来的研究应侧重于重度的抑郁症受试者,并需要有更高的统计效力。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779752, encodeId=a2c01e7975256, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jun 23 17:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012144, encodeId=1d21201214460, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 29 00:16:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632510, encodeId=26051632510da, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Nov 05 10:16:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878191, encodeId=6d6518e81915e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 22 11:16:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152594, encodeId=92fe15259487, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Nov 01 10:16:11 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152167, encodeId=739f15216e56, content=不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Oct 30 10:16:37 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338450, encodeId=80b11338450b7, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568385, encodeId=ee77156838500, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779752, encodeId=a2c01e7975256, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jun 23 17:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012144, encodeId=1d21201214460, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 29 00:16:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632510, encodeId=26051632510da, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Nov 05 10:16:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878191, encodeId=6d6518e81915e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 22 11:16:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152594, encodeId=92fe15259487, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Nov 01 10:16:11 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152167, encodeId=739f15216e56, content=不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Oct 30 10:16:37 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338450, encodeId=80b11338450b7, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568385, encodeId=ee77156838500, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779752, encodeId=a2c01e7975256, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jun 23 17:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012144, encodeId=1d21201214460, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 29 00:16:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632510, encodeId=26051632510da, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Nov 05 10:16:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878191, encodeId=6d6518e81915e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 22 11:16:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152594, encodeId=92fe15259487, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Nov 01 10:16:11 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152167, encodeId=739f15216e56, content=不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Oct 30 10:16:37 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338450, encodeId=80b11338450b7, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568385, encodeId=ee77156838500, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779752, encodeId=a2c01e7975256, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jun 23 17:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012144, encodeId=1d21201214460, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 29 00:16:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632510, encodeId=26051632510da, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Nov 05 10:16:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878191, encodeId=6d6518e81915e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 22 11:16:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152594, encodeId=92fe15259487, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Nov 01 10:16:11 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152167, encodeId=739f15216e56, content=不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Oct 30 10:16:37 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338450, encodeId=80b11338450b7, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568385, encodeId=ee77156838500, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]
    2017-06-22 仁者大医
  5. [GetPortalCommentsPageByObjectIdResponse(id=1779752, encodeId=a2c01e7975256, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jun 23 17:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012144, encodeId=1d21201214460, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 29 00:16:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632510, encodeId=26051632510da, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Nov 05 10:16:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878191, encodeId=6d6518e81915e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 22 11:16:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152594, encodeId=92fe15259487, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Nov 01 10:16:11 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152167, encodeId=739f15216e56, content=不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Oct 30 10:16:37 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338450, encodeId=80b11338450b7, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568385, encodeId=ee77156838500, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]
    2016-11-01 xyfg98

    谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1779752, encodeId=a2c01e7975256, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jun 23 17:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012144, encodeId=1d21201214460, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 29 00:16:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632510, encodeId=26051632510da, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Nov 05 10:16:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878191, encodeId=6d6518e81915e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 22 11:16:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152594, encodeId=92fe15259487, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Nov 01 10:16:11 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152167, encodeId=739f15216e56, content=不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Oct 30 10:16:37 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338450, encodeId=80b11338450b7, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568385, encodeId=ee77156838500, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]
    2016-10-30 1e10c84am36(暂无匿称)

    不错,值得拜读

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1779752, encodeId=a2c01e7975256, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jun 23 17:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012144, encodeId=1d21201214460, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 29 00:16:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632510, encodeId=26051632510da, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Nov 05 10:16:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878191, encodeId=6d6518e81915e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 22 11:16:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152594, encodeId=92fe15259487, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Nov 01 10:16:11 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152167, encodeId=739f15216e56, content=不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Oct 30 10:16:37 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338450, encodeId=80b11338450b7, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568385, encodeId=ee77156838500, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1779752, encodeId=a2c01e7975256, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Jun 23 17:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012144, encodeId=1d21201214460, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 29 00:16:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632510, encodeId=26051632510da, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Nov 05 10:16:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878191, encodeId=6d6518e81915e, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Jun 22 11:16:00 CST 2017, time=2017-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152594, encodeId=92fe15259487, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Nov 01 10:16:11 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152167, encodeId=739f15216e56, content=不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Oct 30 10:16:37 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338450, encodeId=80b11338450b7, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568385, encodeId=ee77156838500, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Sun Oct 30 02:16:00 CST 2016, time=2016-10-30, status=1, ipAttribution=)]

相关资讯

2016阿尔茨海默病创新药物临床试验中国专家共识发布

AD发病机制尚不明确,目前已上市的治疗药物仅4种(多奈哌齐、加兰他敏、卡巴拉汀以及美金刚),均以改善AD临床症状为主,迄今尚无可逆转或阻止病情进展的有效药物。有研究表明,在AD症状出现前的10 ~ 20年即有病理生理改变,因此近年来临床对 AD 的诊断和治疗干预研究,已经从痴呆阶段前移到轻度认知功能障碍(mild cognitive impairment,MCI)阶段以及无症状的临床前AD阶段。2

AAIC 2016:两项研究证实嗅觉识别测试可早期检测阿尔茨海默氏病

据阿尔茨海默病协会国际会议上的两项研究表明,嗅觉识别测试可检测认知障碍和阿尔茨海默氏病,因此,或可改善早期阿尔茨海默氏病的检测和管理。 阿尔茨海默氏症协会医学和科学运营总监Heather Snyder博士说道,“围绕在阿尔茨海默氏病的生物检测的科学正不断进步并得到验证。低成本,非侵入性的方法以检测老年痴呆症相关的改变,并评估未来风险的下降将继续得到完善和测试;这些研究对于阿尔茨海默氏病的早期

Cell Rep:得了阿尔茨海默病的斑马鱼还能再生神经元?德国科学家破解其中机制

来自德国的研究人员最近在阿尔茨海默病研究方面取得重要进展,他们发现了发病的斑马鱼脑部如何通过形成更多神经元应对这种疾病。IL-4和STAT6这两个蛋白与上述过程有关。这项研究在理解、预防甚至治愈阿尔茨海默病方面迈出了一大步。相关研究结果发表在国际学术期刊Cell Reports上。该研究以斑马鱼为研究模型,斑马鱼的脑可以再生,受到不同类型的损伤之后仍然有补充损失的神经元的能力,研究人员发现斑马鱼

J Intern Med:亚洲阿尔茨海默病和脑血管病共存的专家共识

学术界越来越多的人意识到阿尔茨海默病和脑血管病(AD+CVD)的共存,但是由于尚缺乏明确的诊断标准和治疗指南,所以亚洲的AD+CVD患者可能被低估。 来自9个亚太地区国家的16名老年痴呆症专家在2014年9月完成了一项调查,并于2014年11月进行会面,回顾亚洲AD+CVD的流行病学、诊断和治疗方法。通过讨论得出共识,已发表的文献为共识提供证据支持。 数据显示,所有亚洲痴呆症患者中,A

J Alzheimers Dis:AD患者是否有抑郁症,其神经免疫调节机制也不同

抑郁症与阿尔茨海默氏病(AD)共存可恶化AD。中性粒细胞明胶酶蛋白(NGAL)是一种新发现的在AD和抑郁症的病理生理学(神经)炎症调节因子。本研究旨在比较健康对照组,AD没有抑郁(AD-D)及AD合并抑郁症(AD+ D)患者NGAL水平。评估健康对照组(n = 19  ),AD-D(n = 19)及AD+ D(n = 21)患者九个脑区NGAL及其受体蛋白24p3r和Megalin水平。在AD-D

FEBS J:抵抗阿尔茨海默病的新策略

阿尔茨海默病(Alzheimer's disease, AD)是一种起病隐匿的渐进性发展的神经系统退行性疾病。临床初症状表现为记忆力下降、日常生活能力产生障碍,最终将卧床不起、大小便失禁,完全需要依赖家人的照顾,病因迄今未明。在65岁以前发病,称为早老性痴呆;在65岁以后发病,称为老年性痴呆。目前只能通过药物缓解大脑萎缩,还没有治愈的方法,确诊后的平均生存期为10年。据估计,我国现有1000多万老